与抗生素治疗相关的后回性脑病综合征:一个病例报告和系统审查
Lorenzo Barba1, Carmelo Carrubba1, Kai Spindler2
1Department of Neurology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
概括
后回性脑病综合征 (PRES) 可能由抗生素引发. 在大多数与抗生素相关的PRES病例中,迅速诊断和戒药会带来有利的结果.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 放射学 放射学是一门学科.
背景情况:
- 后回性脑病综合征 (PRES) 是一种急性神经疾病,其原因多种多样,包括使用抗生素.
- 关于抗生素相关的PRES现有数据主要来自有限的病例报告和小系列.
- 这项研究提出了一个新案例,并对抗生素相关的PRES进行了系统审查.
结论:
- 与抗生素相关的PRES与经典的PRES具有共同的特征.
- 及时诊断和停止使用违规抗生素至关重要.
- 大多数患者 (90.0%) 经历了完全或几乎完全的康复,突出显示了一般的良好预后.
更多相关视频
09:57Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
2.6K
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
503
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
176
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
176
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
287
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
287
